Anthelmintic activity of injectable eprinomectin (eprecis® 20 mg/mL) in naturally infected dairy sheep

A single subcutaneous dose of eprinomectin (Eprecis®) is effective against common gastrointestinal nematodes and lungworms in experimentally infected lactating goats

BACKGROUND

The health and productivity of dairy goats continue to be impacted by gastrointestinal nematodes (GIN) and lungworms (LW). Eprinomectin (EPN) is frequently selected for treatment because it is generally effective and does not require a milk withdrawal period. However, some factors, such as lactation, can have an impact on EPN pharmacokinetics and potentially its efficacy. To evaluate whether this can alter the efficacy of Eprecis® 2%, an eprinomectin injectable solution, a study was performed in lactating goats using the dose currently registered in cattle, sheep and goats (0.2 mg/kg).

METHODS

This study was a blinded, randomized, controlled trial performed according to the VICH guidelines. Eighteen (18) worm-free lactating goats were included and experimentally challenged on day 28 with a mixed culture of infective gastrointestinal and lung nematode larvae (Haemonchus contortus, Trichostrongylus colubriformis, Teladorsagia circumcincta, Dictyocaulus filaria). At D-1, fecal samples were collected to confirm patent infection in all animals. On D0, the goats were randomly allocated into two groups of nine goats; group 1 was treated with Eprecis® 2% at 0.2 mg/kg BW by subcutaneous injection, while group 2 remained untreated. Fecal samples for egg counts were collected from all animals on days 3, 5, 7, 9, 11 and 14. On D14, all goats were killed, and the abomasum, small intestine and lungs were removed, processed and subsampled to record the number and species of worms.

RESULTS

The treatment was well tolerated. After treatment, the arithmetic mean FEC decreased in the treated group and remained < 5 EPG until the end of the study, while the arithmetic mean FEC in the control group remained > 849.0 EPG. At D14, goats in the treated group had very limited or zero total worm counts, whereas all animals from the control group had a high worm burden. The measured efficacy was 100.0% against H. contortus and T. colubriformis, 99.9% against T. circumcincta and 98.0% against D. filaria.

CONCLUSIONS

Eprinomectin (Eprecis®, 20 mg/ml), administered at the label dose (0.2 mg/kg), is highly effective against gastrointestinal nematodes and lungworms in lactating goats.

Effect of injectable eprinomectin on milk quality and yield of dairy ewes naturally infected with gastrointestinal nematodes

The objective was to investigate the effect of injectable eprinomectin on milk yield and quality of dairy ewes naturally infected with gastrointestinal nematodes when grazing in communal pastures. Onehundred and fifty (150) clinically healthy adult lactating ewes, equally selected from 3 farms, were included in the study. On day -7, the ewes on each farm were randomly allocated into 2 equal groups of 25 animals (n=50): Control group (C) and Treated group (T). On day 0, ewes in group T were given a single subcutaneous injection of eprinomectin at a dose rate of 0.2 mg/kg bodyweight. Ewes in group C were left untreated during the whole experiment. Ewes in group T with a fecal egg count (FEC) >300 eggs per g on day +60 were treated again. Fecal samples were individually collected on days -7, 0, +30, +60, +90, +120 for FEC estimations and coprocultures. On days -7, 0, +30, +60 and +90, individual milk yield (MY) was recorded using ICAR approved volumetric milk meters. Energy corrected milk yield (ECMY) for 6% fat was also calculated. Moreover, individual milk samples were collected on each day for determination of chemical composition [fat (F%), protein (P%) and lactose (L%) content] and somatic cell counts (SCC). On each day, individual fat and protein yield (FY and PY, respectively) were calculated. Total lactation MY, total ECMY, total FY and total PY were computed. The most prevalent parasite at pre-treatment and post-treatment days was Haemonchus spp. The overall efficacy on days +30 and +90 was 97.27 % and 98.80 %, respectively. In two out of the three farms, 80 % and 91.3 % of T ewes received a second treatment on day +60, due to high parasitic burden. Treatment had a significant effect (P=0.033) on MY with an average benefit of 8%. No significant effects of treatment were observed on the other parameters, although values were constantly numerically higher for treated ewes compared to control ones. In this field trial, injectable eprinomectin had a high overall efficacy and a beneficial effect on daily milk yield.

Eprinomectin nanoemulgel for transdermal delivery against endoparasites and ectoparasites: preparation, in vitro and in vivo evaluation

Nanoemulgels are composed of O/W nanoemulsion and hydrogels and are considered as ideal carriers for the transdermal drug delivery because these have high affinity to load hydrophobic drugs. The stable formulation of eprinomectin (EPR) is very challenging because of it is high hydrophobic nature. In this work, we have prepared EPR loaded nanoemulgel for the treatment of endo- and ectoparasites. The surface morphology of optimized formulations was characterized by scanning electron microscopy. Additionally, skin permeability and irritation tests were conducted for in vitro safety and in vivo skin retention and pearmeation test of EPR nanoemulgel were conducted for efficacy study. Obtained results indicated that the optimized formulation had good shear-thinning behavior, bioadhesiveness properties, and are nanosized droplets with porous internal structure, which are required for topical application. Furthermore, this formulation has showed good skin permeability in comparison to suspension and has no skin irritating property. Overall, the obtained results proved that nanoemulgel is a promising carrier for transdermal drug delivery and EPR nanoemulgel is a promising formulation for the treatment of endo- and ectoparasites.

First report of multiple resistance to eprinomectin and benzimidazole in Haemonchus contortus on a dairy goat farm in France

Pour-on eprinomectin was recently registered for lactating small ruminants. Given the high prevalence of benzimidazole resistance in gastrointestinal nematodes in dairy goats, many farmers use eprinomectin exclusively to treat their animals. On a French dairy goat farm, a veterinary practitioner noted a poor response to two types of eprinomectin treatment (pour-on application and injectable formulation). Therefore, we evaluated the efficacy of both formulations of eprinomectin, as well as moxidectin and fenbendazole, using the fecal egg count reduction test (FECRT) according to the World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines. Nematode species were identified at days 0 and post-treatment days 14 after bulk larval cultures, by morphology and real-time PCR. Plasma concentrations of eprinomectin were analyzed by high-performance liquid chromatography (HPLC) at post-treatment days 2 and 5 in the eprinomectin-treated groups. Egg count reductions were poor in animals treated with topical (-16.7%; 95% CI:[-237; 59]) or subcutaneous (21.5%; 95% CI:[-126; 73]) eprinomectin, and with fenbendazole (-5.8%; 95% CI:[-205; 63]). Haemonchus contortus was the main species identified by morphology and by real-time PCR before and after treatment. The plasma concentrations of eprinomectin were determined in all eprinomectin-treated animals and were above 2 ng/ml at post-treatment day 2, indicating that the lack of effect was not due to low exposure of the worms to the drug. Interestingly, moxidectin remained effective in all infected animals. This is the first report of multiple resistance to eprinomectin and benzimidazole in H. contortus on a French dairy goat farm with moxidectin as a relevant alternative.